68% Of Industrial Companies Are Accelerating Deployment of Augmented Reality to Improve Worker Productivity Says New Industry Survey
PTC (NASDAQ: PTC) today announced the release of its 2019 “State of Industrial Innovation” report series. The series provides an ongoing review and analysis of the industrial augmented reality (AR) and industrial internet of things (IIoT) markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005784/en/
PTC releases 2019 State of Industrial Innovation report series. (Graphic: Business Wire)
Among the findings included in the latest “State of Industrial Augmented Reality” report: AR adoption has become focused on delivering enhanced methods of instruction, guidance, and training for front-line workers, enabling the workforce optimization necessary to address the growing skilled labor shortage the industrial sector faces. According to the “State of the Industrial Internet of Things” report: IIoT is poised to have a breakout year in 2019 as companies seek to improve operational effectiveness, reduce costs, and decrease risk inherent in the modern competitive landscape. Both reports explore the breadth of the increasingly multifaceted opportunities presented by these markets.
“Organizations in industrial settings realize the urgency in improving productivity and streamlining operations to remain competitive and relevant,” said Jim Heppelmann, president and CEO, PTC. “The insights offered in these reports validate that the adoption of industrial AR and IIoT is an important step toward achieving these goals.”
Highlights from the Report Findings:
The State of Industrial Augmented Reality
- Industrial enterprises are the highest adopters of augmented reality, comprising nearly 60% of the survey responses, with efforts focused on improving worker performance and solving the skilled labor shortage faced by companies worldwide.
- 55% of use cases aimed at improving worker productivity focus on delivering instructions and guidance primarily within manufacturing, service, and training environments.
- Successful pilots are being moved to production within 12 months at a 20% higher rate, year-over-year, allowing early-movers to capitalize on the competitive advantage.
The State of the Industrial Internet of Things
- IoT is becoming commonplace in heavy-industrial environments, with applications expanding across discrete manufacturing in industrial factories representing over 70% of the survey responses.
- Comprehensive, pre-built IIoT solutions are driving more established use cases, such as operational intelligence (31% of total use cases), as well as emerging use cases, such as predictive maintenance (12%) across manufacturing, operations, and service functions.
- Data processing at the device or “edge-layer” (present in 68% of use cases) is a critical capability for solution providers and there are increasing requirements for the same capabilities at the IoT Gateway (37%) and Cloud (34%) layers.
- Industrial enterprises facing global pressures are seeing the need to quickly deploy IIoT to improve operational effectiveness. 89% of respondents to the 2018 IIoT survey are planning to move to production in the next year, up 6% from 2017.
Leveraging PTC’s 30+ years of technology experience and incorporating data from a cross-section of over 30,000 PTC global customers and 1,000 PTC technology and service partners, PTC’s “State of Industrial Innovation” report series provides a comprehensive view of actionable insights and trends across the industrial ecosystem. To learn more about how industrial AR and IIoT can improve workforce optimization and operational effectiveness, download the “State of Industrial Augmented Reality” and the “State of the Industrial Internet of Things” 2019 reports.
Additional Resources
- Blog: State of Industrial Augmented Reality 2019 Report Highlights Use Cases in Industrial Enterprises
- Blog: State of Industrial Internet of Things 2019 Report Identifies Key Use Cases Driving Operational Effectiveness
- Harvard Business Review: “Why Every Organization Needs an AR Strategy,” authored by PTC CEO Jim Heppelmann and Harvard Professor Michael Porter
About PTC (NASDAQ: PTC)
PTC unleashes industrial innovation
with award-winning, market-proven solutions that enable companies to
differentiate their products and services, improve operational
excellence, and increase workforce productivity. With PTC, and its
partner ecosystem, manufacturers can capitalize on the promise of
today’s new technology to drive digital transformation.
PTC, the State of Industrial Innovation series, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005784/en/
Contact information
PTC
Corporate Communications
Jack McAvoy
jmcavoy@ptc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AdvanCell to participate in Jefferies Global Healthcare Conference in London11.11.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025. The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion. “It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We loo
The Future Is Set for Tourism’s Next Era as the Inaugural TOURISE Summit Opens11.11.2025 14:51:00 EET | Press release
With the bold ambition to rewrite the rules of travel, the inaugural TOURISE Summit under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister was officially opened today by H.E. Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111716065/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, opens the inaugural TOURISE Summit in Riyadh. TOURISE ushers in a new era for global tourism, uniting ministers, delegates, and visionaries from around the world as the premier platform dedicated to shaping the future of global tourism. Taking place from November 11-13, 2025, immediately following the 50th United Nations Tourism General Assembly, TOURISE is reimagining the way that sectors interact to find opportunities where competitors become partners
Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 14:39:00 EET | Press release
The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower
Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 14:06:00 EET | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc
FDA Approves Promega OncoMate ® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA ® in Combination with LENVIMA ® In Advanced Endometrial Carcinoma11.11.2025 14:00:00 EET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with the right therapy,” says Alok Sharma, Global Clinical Market Director at Promega. “We are committed to delivering reliable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom